Combined local therapy and CAR-GPC3 T-cell therapy in advanced hepatocellular carcinoma: a proof-of-concept treatment strategy

Cancer Commun (Lond). 2023 Sep;43(9):1064-1068. doi: 10.1002/cac2.12472. Epub 2023 Jul 21.

Authors

Yaoping Shi¹, Donghua Shi¹, Jiachang Chi¹, Dan Cui¹, Xiaoyin Tang¹, Yan Lin¹, Siying Wang², Zonghai Li^{2

3}, Haojie Jin², Bo Zhai¹

Affiliations

¹ Department of Interventional Oncology, State Key Laboratory of Systems Medicine for Cancer, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P. R. China.
² Shanghai Cancer Institute, State Key Laboratory of Systems Medicine for Cancer, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P. R. China.
³ CARsgen Therapeutics Ltd., Shanghai, P. R. China.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Carcinoma, Hepatocellular* / therapy
Cell Line, Tumor
Cell- and Tissue-Based Therapy
Glypicans
Humans
Immunotherapy, Adoptive
Liver Neoplasms* / therapy

Substances

GPC3 protein, human
Glypicans

Associated data

ClinicalTrials.gov/NCT02395250